Category: 8. Health

No one will argue against the benefits of good oral hygiene (The Guardian view on the dental divide: ministers must brush up their policy as well as children’s teeth, 2 September), but teaching toothbrushing at breakfast clubs to prevent dental decay (cavities and fillings) is a waste of time unless it is backed up by dietary advice with regard to unnecessary sugar. Why can’t this simple advice, and ways to apply it, be given to pregnant women and mothers of newborns? It can be given by a variety of healthcare professionals, costs nothing to apply at home and would save the NHS millions in a few years’ time. Children would have less pain and dentists would have a happier job.

Extending the sugar tax and challenging the aggressive marketing and lobbying tactics of the food industry, which promotes and profits from high-sugar foods, should also be considered if we are to take the problem seriously. There is “no specific correlation between the number of NHS dentists and young children with tooth decay” because the damage has been done and habits established before most children get to see a dentist.

Incidentally, a bit more advice at the earliest stages would have significant health benefits in other respects too.
Nick Hopkinson
York

A newly discovered “timekeeper” for fighting infections dramatically shapes the body’s immune defenses, offering insight as to why antiviral T cell response varies throughout the day, according to UT Southwestern Medical Center researchers. Their findings, published in Science Advances, could lead to new strategies for treating infections, using immunotherapies to combat cancer, and limiting the effects of body clock disruptors such as jet lag and shift work.

The scientists found that a protein on the surface of T cells that binds to adrenaline appears to act as a timekeeper for the cells’ infection-fighting function. This pathway suppresses inflammation while also increasing vulnerability to disease. The discovery could help explain why individuals might be more susceptible to some infections or experience more severe symptoms at various times during a 24-hour period.

“The adrenaline receptor sets the internal clock of virus-specific T cells, which regulates how well they respond to viral infections at different times of the day,” said David Farrar, Ph.D., Associate Professor of Immunology and Molecular Biology at UT Southwestern. Dr. Farrar co-led the study with Drashya Sharma, Ph.D., Instructor of Immunology at UTSW.

Most organisms have biological functions that cycle on a 24-hour time frame, a phenomenon known as circadian rhythm. For humans and many other mammals, light sets these cycles by programming a region of the brain that sends chemical signals throughout the body to synchronize the circadian clocks in cells, tissues, and organs.

Although scientists have long known the immune system functions on its own daily cycle – for example, vaccines tend to elicit a greater immune response when given in the morning than at night – it has not been known which chemical signals regulate its circadian clock.

Dr. Farrar and his colleagues got their first clues in a study they published in 2022. To better understand the role of the adrenaline receptor on T cells, they used genetic engineering to remove this receptor (ADRB2) from T cell surfaces. Surprisingly, among more than 300 genes affected by this change, the researchers found several genes important for maintaining circadian rhythms.

In the new study, Drs. Farrar and Sharma and their colleagues discovered that deleting ADRB2 had an inconsistent effect on these circadian clock genes. While some lost their rhythmic expression, others adopted abnormal rhythms, either shifting when they were normally expressed within a 24-hour cycle or cycling outside a 24-hour period.

Next, healthy, normal mice and others genetically altered to remove ADRB2 from their T cells were infected with vesicular stomatitis virus, a common pathogen for this species. T cells of the mice with ADRB2 proliferated and differentiated into various subsets, as typically happens after exposure to bacterial and viral pathogens; however, T cells of the mice lacking ADRB2 had reduced proliferation and differentiation.

One subset particularly affected in the altered mice was memory T cells, which are targeted by vaccines. These cells stick around after infection, preserving a cellular memory of the pathogen so they can launch a new attack upon exposure to the same pathogen in the future.

Drs. Farrar and Sharma explained that adrenaline produced by brain cells rises upon waking and falls at bedtime, a cycle that’s the opposite of immune activity. Because some circadian clock genes in T cells continue to cycle even in the absence of ADRB2, the researchers added, adrenaline is probably just one of several chemical signals that direct circadian rhythms in T cells.

Future research in the Farrar Lab will focus on identifying other cycle-setting chemicals in these immune cells as well as how they affect T cell response to various pathogens at different times of the day.

Reference: Sharma D, Kohlbach KA, Maples R, Farrar JD. The β2-adrenergic receptor (Adrb2) entrains circadian gene oscillation and CD8+ T cell differentiation in response to virus infection. Science Advances. 2025;11(31):eady2643. doi: 10.1126/sciadv.ady2643

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.

Researchers have developed a shampoo-like gel that has been studied in animal models and could protect hair from falling out during chemotherapy treatment.

Baldness from chemotherapy-induced alopecia causes personal, social, and professional anxiety for everyone who experiences it.

Currently, there are few solutions—the only ones that are approved are cold caps worn on the patient’s head, which are expensive and have their own extensive side effects.

Bryan Smith, an associate professor in the Michigan State University College of Engineering and with MSU’s Institute for Qualitative Health Science and Engineering, has developed a gel the consistency of shampoo that he hopes will help protect patients’ hair throughout treatment.

When Smith was a trainee at Stanford University, he learned and used a process that inverted the typical engineering process, seeking to objectively identify and completely characterize critical clinical needs prior to solving them.

“This unmet need of chemotherapy-induced alopecia appealed to me because it is adjacent to the typical needs in medicine such as better treatments and earlier, more accurate diagnostics for cancer,” Smith says.

“This is a need on the personal side of cancer care that, as an engineer, I didn’t fully recognize until I began interviewing cancer physicians and former cancer patients about it. Once I understood, it became clear to me that better solutions are very important to many cancer patients’ quality of life.”

This rigorous process of specifying the need, identifying possible solutions, developing an initial prototype, and refining and testing it led to the development of a gel described in a new paper in Biomaterials Advances.

The gel is a hydrogel, which absorbs a lot of water and provides long-lasting delivery of drugs to the patient’s scalp. The hydrogel is designed to be applied to the patient’s scalp before the start of chemotherapy and left on their head as long as the chemotherapy drugs are in their system—or until they are ready to easily wash it off.

During chemotherapy treatment, chemotherapeutic drugs circulate throughout the body. When these drugs reach the blood vessels surrounding the hair follicles on the scalp, they kill or damage the follicles, which releases the hair from the shaft and causes it to fall out. The gel, containing the drugs lidocaine and adrenalone, prevents most of the chemotherapy drugs from reaching the hair follicle by restricting the blood flow to the scalp. Dramatic reduction in drugs reaching the follicle will help protect the hair and prevent it from falling out.

To support practical use of this “shampoo,” the gel is designed to be temperature responsive. For example, at body temperatures the gel is thicker and clings to the patient’s hair and scalp surface. When the gel is exposed to slightly cooler temperatures, the gel becomes thinner and more like a liquid that can be easily washed away.

Smith and his team hope to obtain federal and/or venture funding to move this research forward into clinical trials and, eventually, to human patients.

“The research has the potential to help many people,” Smith says. “All the individual components are well-established, safe materials, but we can’t move forward with follow-up studies and clinical trials on humans without the support of substantial funding.”

Source: Michigan State University

A single 100 μg dose of MM120 (lysergide D-tartrate, LSD) significantly reduced anxiety symptoms in adults with generalized anxiety disorder (GAD), with improvements sustained through 12 weeks, according to the first randomized, placebo-controlled trial of its kind published today in JAMA.¹

“This study is a true turning point in the field of psychiatry,” investigator Maurizio Fava, MD, member of the MindMed Scientific Advisory Board and chair of Mass General Brigham Department of Psychiatry, said in a statement.² “For the first time, LSD has been studied with modern scientific rigor, and the results are both clinically meaningful and potentially paradigm-shifting for the treatment of GAD.”

Despite 26 million adults in the US diagnosed with GAD, the US Food & Drug Administration (FDA) has not approved a new medication for this indication since 2007.² However, 50% of patients fail first-line GAD treatments.

“I have seen firsthand the devastating toll GAD takes on patients and their families, which is why it is so significant that a single dose of MM120 delivered rapid, robust, and lasting effects,” Fava continued.² “These results highlight the promise of psychedelics in psychiatric medicine.”

MindMed conducted MMED008, a multicenter, randomized, placebo-blind, phase 2b study evaluating a single administration of MM120 at 4 dose levels (25 [n = 39], 50 [n = 40], 100 [n = 40], or 200 [n = 40]) μg as monotherapy, without any psychotherapeutic intervention, in adults with moderate to severe GAD.¹ The sample included 198 adults aged 18 – 74 years (mean age, 41.3 years), with 56.7% female and 83% White (7.7% Black or African American and 3.6% Asian). The dose-response relationship was evaluated using the multiple comparison procedure modeling (MCP-Mod) method for change in Hamilton Anxiety Rating Scale at week 4.

The study met its primary endpoint, with MM120 demonstrating a dose-response relationship at week 4 with the 100 μg (least-squares mean difference, −5.0 points; 95% confidence interval [CI], −9.6 to −0.4 points) and the 200-μg (−6.0 points; 95% CI, −9.8 to −2.0 points) dose groups vs placebo. The study found no significant difference between the 25 μg (least-squares mean difference, −1.2 points; 95% CI, −6.0 to 3.5 points) and 50 μg (−1.8points; 95% CI, −7.6 to 4.0 points) doses compared with placebo.¹

The trial also met its key secondary endpoint, demonstrating a significant symptom improvement versus placebo on the Hamilton Anxiety Rating Scale (HAM-A). The analysis showed that 100 μg was the optimal dose of MM120. At week 4, this dose achieved a 7.6-point greater reduction in HAM-A scores compared to placebo (-21.3 vs. -13.7; P <.0004). Participants on MM120 100 μg had a 65% clinical response rate and a 48% clinical remission rate sustained to week 12.¹

This study also met other secondary outcomes, including clinician-rated disease severity measured by the Clinical Global Impression-Severity (CGI-S) scale, changes from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS), and measures of functional disability and quality of life.

On average, CGI-S scores improved from 4.8 to 2.2 in the 100 μg dose group, reflecting a 2-category shift from “markedly ill” to “borderline ill” at week 12. This was compared to a 4.9 to 3.5 improvement in the placebo group (P =.003).¹

Furthermore, MM120 showed rapid clinical activity, working as early as day 2 and sustained through week 4 and 12. MM120 100 μg also led to significant MADRS improvement vs placebo, with a difference of 5.7 points at week 4 (P ≤.05) and a difference of 6.4 points at week 12 (P ≤.05).¹

The safety profile of MM120 was comparable to previous findings, with mild-to-moderate adverse events occurring on dosing day. Common adverse events included visual perceptual changes, including illusion, pseudo-hallucination, and visual hallucination.¹ These visual perceptual changes occurred in 46.2% of participants who received 25 μg of MM120, 75% who received 50 μg, 92.5% who received 100 μg, 100% who received 200 μg, and 10.3% who received a placebo.

Another common adverse event included nausea, occurring in 7.7% receiving 25 μg, 27.5% receiving 50 μg, 40% receiving 100 μg, 60% receiving 200 μg, and 7.7% receiving placebo.¹ Headaches occurred in 12.8%, 22.5%, 35.0%,27.5%, and 23.1% of participants, respectively.

The dose-response results inform MindMed’s ongoing phase 3 trial focusing on the MM120 Orally Disintegrating Tablet (ODT). Topline results for MindMed’s Voyage trial, evaluating the efficacy, durability, and safety of MM120 ODT for GAD, are expected in the first half of 2026.²

“Our Phase 2b results—marking the first well-controlled clinical study to evaluate dose-response relationships of LSD in a psychiatric population—demonstrate the meaningful impact of a single 100 μg dose of MM120 in significantly reducing anxiety symptoms,” said Daniel Karlin, MD, chief medical officer of MindMed.²

References

1. Robison R, Barrow R, Conant C, et al. Single Treatment with MM120 (Lysergide) in Generalized Anxiety Disorder. JAMA.doi:10.1001/jama.2025.13481. Published online September 4, 2025.

2. Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD). MindMed. Assessed September 4, 2025.

Introduction

Lyme disease (LD) is the most common vector-borne infection in the Northern Hemisphere, leading to substantial economic and medical burdens.¹ In the USA alone, insurance claims for clinician-diagnosed LD rose from approximately 329,000 in 2010 to 476,000 in 2018.^2,3 If left untreated, LD can result in serious complications affecting the skin, joints, nervous system, and heart.^4,5 Although most patients recover fully after antibiotic therapy, a subset experiences persistent symptoms lasting months or even years. This post-treatment manifestation, which remains poorly understood, is the focus of ongoing research due to its clinical and economic implications. Annual medical costs in the United States are estimated at $712 million to $1.3 billion.^6–8

Diagnosing LD can be challenging in the absence of erythema migrans, which is considered pathognomonic for the infection. While erythema migrans appears in the majority of cases, its absence has been reported in both US and European studies. In the United States, 13–18% of early LD cases lacked erythema migrans despite systemic symptoms or laboratory confirmation.^9,10 Population-based data from Germany indicate that approximately 11% of cases lack classic erythema migrans.¹¹ In such cases, diagnosis relies on two-tiered serological testing, which detects specific antibodies to Borrelia. However, this approach has limitations: IgM appears in only 20–50% of acute cases and peaks 4–6 weeks after onset. Early testing may yield false negatives due to the serology window, immune suppression, or antigenic variability. False positives also occur in various infectious and autoimmune diseases.^12,13

To enhance diagnostic accuracy in patients without erythema migrans, we supplemented serological testing with thermography – a non-invasive technique that records infrared radiation from the body. Thermography detects pathological changes through alterations in thermal distribution, primarily reflecting vascular responses.¹⁴ This method has been explored in diverse medical fields, including oncology, surgery, neurology, rheumatology, dermatology, and infectious diseases.^15–17 A recently published study¹⁸ demonstrated the use of infrared thermography to visualize erythema migrans in patients with early Lyme borreliosis, showing localized hyperthermia and distinct thermal patterns in visible lesions. While that work confirmed the feasibility of thermography in clinically apparent erythema migrans, it did not address cases without visible skin changes.

The aim of the present study is to explore whether this infrared thermography can also detect subclinical cutaneous inflammation at the site of a tick bite in patients lacking erythema migrans.

Patients and Methods

We observed 16 patients with Lyme disease without erythema migrans who received outpatient or inpatient care at the Infectious Disease Department of the Ternopil City Communal Hospital of Emergency Medicine. The diagnosis was based on clinical history (notably, tick bites confirmed by visits to the hospital’s trauma center for tick removal) and laboratory findings (positive two-tiered Lyme disease serologic testing results)¹⁹ in serum samples taken 10–20 days after the bite. At the time of sampling, hyperemia at the site of the bite was typically resolved, and no visible erythema migrans was present. Antibodies to B. burgdorferi sensu lato (s.l). complex antigens in the blood serum of patients were detected using enzyme-linked immunosorbent assay (ELISA) with test systems from Euroimmun AG (Germany): IgM antibodies were determined using the Anti-Borrelia burgdorferi ELISA (IgM) test, and IgG antibodies using the Anti-Borrelia plus VIsE ELISA (IgG) test.

A control group consisted of 22 individuals who had experienced a tick bite but tested seronegative for Borrelia burgdorferi (serum IgM and/or IgG antibodies negative on samples taken 10–20 days after the bite). These controls were representative of the patient group in terms of age and sex distribution.

All subjects completed a questionnaire that included personal information, as well as history details about the time, place, and circumstances of the tick bite, along with any prior treatment. Participation in the study was based on voluntary consent.

Thermographic Assessment

It was hypothesized that Borrelia, after penetrating the skin during a tick bite, causes minimal local inflammation. Even in the absence of visible hyperemia, this inflammation may still be associated with a localized increase in body temperature, or “warming”, which can be detected by infrared thermography. Initial thermography was performed at the same visit when the first serology sample was taken (10–20 days after the bite), before results were available, to assess its potential as an early detection method.

Preparation for thermography and the examination itself followed the guidelines provided by the manufacturer, ULIRvision (China).²⁰ Patients refrained from physiotherapy, massage, vasoactive drugs, and topical preparations for at least 24 hours, and from smoking or eating for 40–60 minutes before the examination. The room temperature was maintained at 18–22 °C, with a 10–15 minute acclimatization period. The camera was positioned 100–150 cm from the site of interest. The focus was on the site of tick attachment and surrounding tissues. For paired areas (eg, limbs or lateral sides of the torso), the symmetrical part of the body was also examined.

Thermal images were initially analyzed visually by comparing color patterns to those of surrounding areas. In cases where thermal asymmetry was observed, the thermograms were described using the following criteria: presence of asymmetry, localization of areas with increased or decreased infrared radiation intensity, absolute temperature values, and differences relative to the symmetrical area. Subsequently, the images were processed using IRSee software, which automatically recorded temperature values at all points within the image. For greater precision, thermographs and histograms were used to present temperature distributions in the region of interest, as well as in specific points. When analyzing the area of interest, the shape (focal or diffuse), uniformity (homogeneous or heterogeneous), and contour clarity (clear or fuzzy) of the thermally active region were considered. The system can simultaneously process up to 20 point objects, 10 lines, 20 fields, and 10 polygonal or elliptical shapes. To compare symmetrical areas or the thermographically detected warm focus with surrounding tissues, points, horizontal lines, and oval fields were primarily used. The temperature at marked points was recorded, enabling the calculation of the temperature difference (ΔT) along the line of interest. A temperature difference (ΔT) of more than 0.5 °C between symmetrical areas is considered indicative of localized inflammatory activity, as described in previous studies.^15,21,22 Extreme values (maximum and minimum temperatures) were automatically indicated, and an oval field enabled the construction of a histogram that visually represented the temperature distribution from minimum to maximum. Processed thermograms were stored in an electronic archive for future comparison during patient follow-up. All study subjects, both patients and controls, underwent repeat examination 3–4 months after the initial visit.

Results

The patients ranged in age from 20 to 62 years, with an average age of 36.8 ± 3.4 years. Among the participants, 7 (43.8%) were men and 9 (56.2%) were women. Thermography of the affected areas in all 16 patients with the non-erythematous form of LB revealed hyperthermia (local inflammation of the skin) around the tick bite site in the form of a ring-shaped zone of higher temperature (ΔT = 0.6–3.8°C) resembling erythema migrans. This annular thermal pattern persisted for at least two weeks, even after antibacterial therapy. In approximately one-third of the patients, ΔT ranged from 0.6 to 1.1°C; in half, it ranged from 1.2 to 1.6°C; and in 18.7% of cases, ΔT exceeded 1.6°C (Table 1).

Table 1 Results of Thermal Imaging Examination of Tick Bite Sites in Patients with Non-Erythematous Form of LB (n=16)

In 17 of the 22 seronegative controls, a primary hyperemia at the site of tick attachment was observed but resolved spontaneously or after desensitizing therapy within 3–7 days. The remaining five controls did not develop hyperemia at the bite site. Thermographic examination performed 10–20 days after the bite revealed no abnormal localized warming in any control subject. A follow-up thermographic assessment conducted 3–4 months after the initial visit likewise revealed no local hyperthermia or pathological thermal asymmetry in either the patient or control groups. The transient hyperemia observed in 17 control individuals is consistent with a typical short-lived allergic reaction to the bite rather than infection-related inflammation.

Illustrative Case Study

A 36-year-old male, presented with a history of a tick bite, which had been successfully removed at the trauma center of the Ternopil City Municipal Emergency Hospital. The tick measured over 6 mm, indicating a prolonged attachment (more than 3 days). At the site of the bite (Figure 1A), a hyperemic spot approximately 5 mm in size was observed, which appeared to be an allergic reaction to the tick bite. No erythema migrans was noted.

Figure 1 Primary lesion at the site of a tick bite (A) and the corresponding hot spot (automatically marked with a cross) on the thermogram of the affected leg (B) of the patient with Lyme borreliosis, where erythema migrans is absent, but localized inflammation is detected through thermography (suberythematous form).

Thermography during this period revealed significant hyperthermia (ΔT = 1.1°C) at the site of the bite, coinciding with the hyperemic spot’s outline (Figures 1B and 2). No antibiotics were administered at this stage, and serological tests (ELISA) did not initially confirm the presence of specific antibodies to Borrelia burgdorferi s.l. However, a follow-up serological examination after 30 days, using both ELISA and immunoblot, showed seroconversion of IgM and IgG antibodies against B. burgdorferi s.l. This, combined with the unaltered appearance of the skin on the lower leg (Figure 3A), led to a diagnosis of the cutaneous, non-erythematous form of Lyme borreliosis.

Figure 2 Analysis of the thermogram of the patient using IRSee Software. Upper left corner (A) Infrared image with line L1 (indicating the warming epicenter) and the zone of interest E1 (surrounding area) encircled by an ellipse; markings L1 and E1 represent measurement points as displayed in the software during analysis. Center upper section (B) Tick bite site on the left shin showing a primary lesion without erythema migrans. Upper right corner (C) Histogram of temperatures within zone E1 (surrounding tissue near the bite site), ranging from 29.1 to 30.6 °C, shown as relative frequency (%). Lower left corner (D) Display of the obtained indicators. Center lower section (E) Temperature palette corresponding to the different temperature values. Lower right corner (F) Temperature plot along line L1, showing temperatures from 29.5 to 30.6 °C.

Figure 3 (A) Absence of any visible changes in the skin of the left shin of the patient 30 days after the tick bite; (B) infrared thermogram of the patient: despite the absence of visible erythema migrans, the annular hyperthermia is visible, corresponding to the pathognomonic erythema migrans rash, not detectable to the unaided eye.

Subsequent thermographic analysis of the left lower leg revealed local rounded hyperthermia in the form of a concentric circle with a diameter of up to 7 cm (ΔT = 0.8°C, Figures 3B and 4). Fourteen days after the completion of doxycycline hydrochloride therapy (200 mg per day, divided into two 100 mg doses for 2 weeks), the local hyperthermia at the tick bite site resolved, as confirmed by a follow-up thermogram (Figure 5). Repeat thermographic assessment performed 34 days later (64 days after the tick bite) showed a normal thermal distribution without any signs of abnormal thermal asymmetry.

Figure 4 Thermogram of the left shin of the patient depicting the ring-shaped infrared glow, a thermographic pattern in which a distinct ring of increased temperature surrounds the area of inflammation, with a moderate temperature difference (∆T=0.8 °C), despite the absence of visible erythema. Upper left corner (A) Infrared image of the same area as in Figure 2A (line L1 and the zone of interest E1 within the ellipse) 30 days after the bite. Center upper section (B) Tick bite site on the left shin with no visible changes 30 days after the bite. Upper right corner (C) Temperature distribution in zone E1 (surrounding tissue near the bite site), ranging from 29.3 to 31.2 °C, shown as relative frequency (%). Lower left corner (D) Display of the obtained indicators. Center lower section (E) Temperature palette corresponding to the different temperature values. Lower right corner (F) Temperature plot along line L1, ranging from 29.3 to 30.1 °C.

Figure 5 Analysis of the thermogram of the left shin of the same patient, 2 weeks after the completion of antibiotic therapy. Upper left corner (A) Infrared image of the same zone as in Figure 2A after completion of therapy. Center upper section (B) Tick bite site on the left shin with unchanged appearance after therapy. Upper right corner (C) Temperature distribution in zone E1 (surrounding tissue near the bite site), ranging from 31.0 to 31.8 °C, shown as relative frequency (%). Lower left corner (D) Display of the obtained indicators. Center lower section (E) Temperature palette corresponding to the different temperature values. Lower right corner (F) Temperature plot along line L1, ranging from 31.4 to 31.7 °C.

Discussion

To our knowledge, this is the first study to investigate the diagnostic utility of infrared thermography in patients with Lyme borreliosis (LB) who do not exhibit the pathognomonic sign of erythema migrans, building on our prior preliminary report²² that proposed this method for forms of the disease lacking visible erythema. In such cases, the absence of cutaneous manifestations significantly complicates timely diagnosis, particularly during the early phase of infection, when serological tests may still yield negative results. In this study, we employed thermography as a non-invasive, radiation-free technique for detecting localized increases in skin temperature suggestive of inflammation. From a practical standpoint, the method is simple, requiring only brief patient acclimatization, basic environmental control, and standard camera positioning. These steps are easily reproducible and demand minimal additional resources. The procedure can be carried out in standard outpatient settings without the need for specialized infrastructure beyond the imaging device itself. In addition to the aforementioned advantages, this method, unlike serological testing, does not depend on the development of a detectable antibody response, making it potentially useful in the very early stages of infection. Our findings suggest that infrared thermography can serve as a practical, noninvasive adjunct to serological testing in suspected Lyme borreliosis, particularly in cases without visible erythema migrans. In addition to the patient cohort, we also evaluated a control group of seronegative individuals with documented tick bites; none demonstrated abnormal localized warming on thermography at either 10–20 days or 3–4 months post-bite, which is consistent with the absence of infection-related inflammation in this group.

The physiological basis for thermographic findings lies in the vascular and metabolic changes associated with inflammation. Skin temperature reflects the underlying dynamics of blood flow, tissue metabolism, and immune activity, with vascular factors being the primary determinant of thermal asymmetry.^15–18

Our findings align with the known pathophysiology of LB. In typical cases, the hematogenous or lymphogenous dissemination of Borrelia from the site of inoculation leads to the development of erythema migrans, mediated by inflammatory cytokines such as TNF-α, IL-1, and IL-6.^20,22 However, the absence of visible erythema in some patients may reflect either a lower inoculum of spirochetes, individual variability in immune response, or its poor visibility on darker skin tones. Nonetheless, the local tissue still mounts a subclinical inflammatory reaction – one that includes warmth (calor) as a cardinal sign of inflammation.^21–24 Thermography appears to capture this subvisible inflammatory process with high sensitivity, as evidenced by the concentric hyperthermic zones we observed around the tick bite sites, even in the absence of clinically evident erythema.

In this context, we propose the descriptive term “suberythematous form” for cases without visible erythema migrans but with thermographically detected annular hyperthermia. While not a formally recognized subtype, this presentation may benefit from early detection via infrared thermography, which could serve as a valuable adjunct to serological testing. The infrared thermography technique is already well-established in other fields eg, oncology, neurology, angiology, and dermatology, among others and its application to infectious diseases has been developed by several groups.^15–18 Our results complement recent works applying infrared thermography to visible erythema migrans lesions, including both single and disseminated forms.^18,25 In contrast, the present study demonstrates that infrared thermography can also reveal localized hyperthermia in the absence of visible erythema, which we define as the suberythematous form of LB. This finding supports emerging evidence that infrared thermography can detect inflammatory changes associated with Borrelia burgdorferi infection even when erythema migrans is not clinically apparent. Importantly, such imaging may be valuable not only when the rash is absent, but also when it is subtle, difficult to discern in visible light, or less apparent in patients with darker skin pigmentation.¹⁸ Given its non-invasiveness, lack of contraindications, and ability to detect otherwise occult inflammation, infrared thermography has potential as a complementary diagnostic tool alongside serology and clinical evaluation in suspected Lyme borreliosis. We did not perform tick testing because the presence of Borrelia burgdorferi in a tick does not guarantee transmission, which typically requires ≥36–48 hours of attachment,²⁶ and negative results cannot reliably exclude infection, as cases of LD have been documented after bites from PCR-negative ticks.²⁷ Future studies with larger cohorts and standardized thermographic criteria are needed to refine diagnostic utility of infrared thermography and define its role within clinical guidelines.

Conclusions

1. Infrared thermography of the tick bite site can visualize the pathognomonic sign of Lyme borreliosis, the annular erythema migrans rash, even when it is not detectable on visual inspection.
2. In patients with Lyme borreliosis who lack visible erythema migrans, thermographic imaging enables the detection of a temperature difference greater than 0.5 °C between the site of the tick bite and adjacent or symmetrical areas of the body.
3. Early thermographic identification of the suberythematous cutaneous form of Lyme borreliosis supports the initiation of etiotropic therapy to prevent the development of long-term complications.

Data Sharing Statement

The data supporting the findings of this study are available from the corresponding author upon reasonable request.

Ethics Approval and Consent to Participate

This study was approved by the Institutional Bioethics Committee of Ivan Horbachevsky Ternopil National Medical University (protocol №. 81 dated April 3, 2025). All patients gave informed consent for participation in the study. Informed consent for publication of the case details and accompanying images was obtained from the patient described in the illustrative case study. The study was conducted in accordance with the ethical standards of the Declaration of Helsinki and its subsequent amendments.

Author Contributions

All authors made a significant contribution to the work reported, including conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the manuscript; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding

This study was not supported by any external funds.

Disclosure

The authors declare that they have no competing interests in this work.

References

1. Gocko X, Lenormand C, Lemogne C, et al. Lyme borreliosis and other tick-borne diseases. Guidelines from the French scientific societies. Med Mal Infect. 2019;49(5):296–317. doi:10.1016/j.medmal.2019.05.006

2. Kugeler KJ, Schwartz AM, Delorey MJ, Mead PS, Hinckley AF. Estimating the frequency of Lyme disease diagnoses, United States, 2010-2018. Emerg Infect Dis. 2021;27(2):616–619. doi:10.3201/eid2702.202731

3. Nelson CA, Saha S, Kugeler KJ, et al. Incidence of clinician-diagnosed Lyme disease, United States, 2005-2010. Emerg Infect Dis. 2015;21(9):1625–1631. doi:10.3201/eid2109.150417

4. Steere AC, Strle F, Wormser GP, et al. Lyme borreliosis. Nat Rev Dis Primers. 2016;2(1):16090. doi:10.1038/nrdp.2016.90

5. Smiyan S, Komorovsky R, Koshak B, Duve K, Shkrobot S. Central nervous system manifestations in rheumatic diseases. Rheumatol Int. 2024;44(10):1803–1812. doi:10.1007/s00296-024-05679-1

6. Adrion ER, Aucott J, Lemke KW, Weiner JP. Health care costs, utilization and patterns of care following Lyme disease. PLoS One. 2015;10(2):e0116767. doi:10.1371/journal.pone.0116767

7. Bobe JR, Jutras BL, Horn EJ, et al. Recent progress in Lyme disease and remaining challenges. Front Med. 2021;8:666554. doi:10.3389/fmed.2021.666554

8. Tick-borne disease working group. report to congress 2018. HHS. 2018. Available from: https://www.hhs.gov/sites/default/files/tbdwg-report-to-congress-2018.pdf. Accessed March 16, 2025.

9. Aucott J, Morrison C, Munoz B, Rowe PC, Schwarzwalder A, West SK. Diagnostic challenges of early Lyme disease: lessons from a community case series. BMC Infect Dis. 2009;9(1):79. doi:10.1186/1471-2334-9-79

10. Steere AC, Sikand VK. The presenting manifestations of Lyme disease and the outcomes of treatment. N Engl J Med. 2003;348(24):2472–2474. doi:10.1056/NEJM200306123482423

11. Huppertz HI, Böhme M, Standaert SM, Karch H, Plotkin SA. Incidence of Lyme borreliosis in the Würzburg region of Germany. Eur J Clin Microbiol Infect Dis. 1999;18(10):697–703. doi:10.1007/s100960050381

12. Stanek G, Strle F. The history, epidemiology, clinical manifestations and treatment of Lyme borreliosis. In: Hunfeld KP, Gray J, editors. Lyme Borreliosis. Cham: Springer; 2022:77–105.

13. Jakubowska K, Janocha A, Jerzak A, Ziemba P. Diagnosis, clinical manifestations and treatment of Lyme disease. Qual Sport. 2024;18:53283. doi:10.12775/QS.2024.18.53283

14. Choi MS, Seong GH, Park MJ, et al. Rapidly progressing generalized morphea with high Lyme disease titer. Indian J Dermatol. 2020;65(5):432–434. doi:10.4103/ijd.IJD_279_18

15. Andreychyn MA, Kopcha Yu V. Remote thermography and its significance for the diagnosis of acute tonsillitis. Infektsiyni khvoroby. 2016;3(85):82–88. Ukrainian. doi:10.11603/1681-2727.2016.3.6897

16. Liu Q, Li M, Wang W, et al. Infrared thermography in clinical practice: a literature review. Eur J Med Res. 2025;30(1):33. doi:10.1186/s40001-025-02278-z

17. Kesztyüs D, Brucher S, Wilson C, Kesztyüs T. Use of infrared thermography in medical diagnosis, screening, and disease monitoring: a scoping review. Medicina. 2023;59(12):2139. doi:10.3390/medicina59122139

18. Brothers NI, Rebman A, Zenilman JM, et al. Use of infrared thermography in visualizing erythema migrans. Cureus. 2025;17(8):e89242. doi:10.7759/cureus.89242

19. U.S. Centers for Disease Control and Prevention. Standard two-tiered testing: suggested result reporting and interpretation. Available from: https://www.cdc.gov/lyme/media/pdfs/2024/05/Standard_Two_Tiered_Testing_Suggested_Results_Reporting_Interpretation.pdf. Accessed May 12, 2025.

20. Thermal imager Xintest HT-18. Available from: https://brom.ua/index.php?route=product/product&product_id=18190. Accessed May 12, 2025.

21. Andreychyn MA, Korda MM. [Lyme Borreliosis: Monograph]. Ternopil: TNMU; 2021:376. Ukrainian.

22. Andreychyn MA, Korda MM, Kopcha VS, Shkilna MI. Method of diagnosis of non-erythematous Lyme disease. Infektsiyni khvoroby. 2020;1(99):16–19. Ukrainian. doi:10.11603/1681-2727.2020.1.11092

23. Nielsen MC, Miller NS. Epidemiology and diagnosis of Lyme disease in the United States. Clin Lab Med. 2025;45(1):137–144. doi:10.1016/j.cll.2024.10.008

24. Strle F, Wormser GP. Early Lyme disease (erythema migrans) and its mimics (southern tick-associated rash illness and tick-associated rash illness). Infect Dis Clin North Am. 2022;36(3):523–539. doi:10.1016/j.idc.2022.03.005

25. Huk MT, Andreychyn MA, Shkilna MI, Zaporozhan SY. Thermographic study of migrating erythema. Sci Bul Uzhhorod Univ Series. 2021;63(1):43–48.

26. Cook M. Lyme borreliosis: a review of data on transmission time after tick attachment. Int J Gen Med. 2015;8:1–8. doi:10.2147/IJGM.S73791

27. Hofhuis A, van de Kassteele J, Sprong H, et al. Predicting the risk of Lyme borreliosis after a tick bite, using a structural equation model. PLoS One. 2017;12(7):e0181807. doi:10.1371/journal.pone.0181807